Product Overview
Composition
Active ingredients:
Magnesium asparaginate 140.0 mg (in the form of magnesium asparaginate • 4 H 2 O - 175.00 mg)
Potassium asparaginate 158.0 mg (in the form of potassium asparaginate • 1/2 H 2 O - 166.30 mg).
Excipients:
Silicon dioxide, colloidal - 2.00 mg, povidone K30 - 3.30 mg, magnesium stearate - 4.00 mg, talc - 10.00 mg, corn starch - 86.10 mg, potato starch - 3.30 mg in the core of the tablets.
Sheath composition:
Macrogol 6000 - 1.40 mg, titanium dioxide Col. ind. 77891, E171 - 5.30 mg, butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate copolymer [1: 2: 1] - 6.00 mg, talc - 7.30 mg.
Magnesium asparaginate 140.0 mg (in the form of magnesium asparaginate • 4 H 2 O - 175.00 mg)
Potassium asparaginate 158.0 mg (in the form of potassium asparaginate • 1/2 H 2 O - 166.30 mg).
Excipients:
Silicon dioxide, colloidal - 2.00 mg, povidone K30 - 3.30 mg, magnesium stearate - 4.00 mg, talc - 10.00 mg, corn starch - 86.10 mg, potato starch - 3.30 mg in the core of the tablets.
Sheath composition:
Macrogol 6000 - 1.40 mg, titanium dioxide Col. ind. 77891, E171 - 5.30 mg, butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate copolymer [1: 2: 1] - 6.00 mg, talc - 7.30 mg.
pharmachologic effect
The most important intracellular cations K + and Mg ++ play a key role in the functioning of numerous enzymes, in the formation of bonds between macromolecules and intracellular structures, and in the mechanism of muscle contractility. The intra- and extracellular ratio of potassium, calcium, sodium and magnesium ions affects myocardial contractility. Endogenous aspartate acts as a conductor of ions: it has a high affinity for cells, due to the slight dissociation of its salts, ions in the form of complex compounds penetrate into the cell. Magnesium and potassium aspartates improve myocardial metabolism. Lack of magnesium / potassium predisposes to the development of hypertension, atherosclerosis of the coronary arteries, arrhythmias and metabolic changes in the myocardium.
Indications
As an additional agent in the treatment of chronic heart disease (heart failure, condition after myocardial infarction), cardiac arrhythmias (primarily ventricular arrhythmias), in the treatment of digitalis; replacement therapy for a lack of magnesium / potassium in food.
Contraindications
Hypersensitivity to any of the constituent components of the drug, acute and chronic renal failure, hyperkalemia, hypermagnesemia, Addison's disease, I-III degree atrioventricular block, cardiogenic shock (blood pressure less than 90 mm Hg), impaired amino acid metabolism, severe myasthenia gravis , hemolysis, acute metabolic acidosis, dehydration.
Carefully
Pregnancy (especially in the first trimester) and during lactation.
Side effects
Possible nausea, vomiting, diarrhea, discomfort or burning sensation in the pancreas (in patients with anacid gastritis or cholecystitis), atrioventricular block, paradoxical reaction (an increase in the number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea, paresthesia) (redness of the face, redness of the face, feeling of thirst, lowering blood pressure, hyporeflexia, respiratory depression, convulsions).
Interaction
Pharmacodynamic: combined use with potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporin, heparin, angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs increases the risk of hyperkalemia and up to the development of asystole arrhythmia. The use of potassium preparations in conjunction with glucocorticosteroids eliminates the hypokalemia caused by the latter. Under the influence of potassium, the undesirable effects of cardiac glycosides are reduced. Strengthens the negative dromo- and batmotropic effect of antiarrhythmic drugs. Magnesium reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin. Anesthetics increase the inhibitory effect of magnesium preparations on the central nervous system; with simultaneous use with atracuronium, decametonium, succinyl chloride and suxamethonium may increase the neuromuscular blockade; calcitriol increases plasma magnesium levels, calcium supplements reduce the effect of magnesium supplements.
Pharmacokinetic: astringent and coating agents reduce the absorption of the drug in the gastrointestinal tract and it is necessary to observe the three-hour interval between taking Panangin ® inside with the listed agents.
How to take, course of administration and dosage
Before use, you should consult your doctor.
Inside, the drug should be used after meals. the acidic environment of the stomach reduces its effectiveness.
The usual daily dose: 1-2 tablets. 3 times a day. Maximum daily dose: 3 tablets 3 times a day.
The duration of the drug intake and the need for repeated courses are determined by the doctor.
Inside, the drug should be used after meals. the acidic environment of the stomach reduces its effectiveness.
The usual daily dose: 1-2 tablets. 3 times a day. Maximum daily dose: 3 tablets 3 times a day.
The duration of the drug intake and the need for repeated courses are determined by the doctor.
Overdose
Symptoms: impaired conduction (especially with previous pathology of the cardiac conduction system).
Treatment: intravenous administration of calcium chloride; if necessary, hemodialysis and peritoneal dialysis.
Treatment: intravenous administration of calcium chloride; if necessary, hemodialysis and peritoneal dialysis.
Special instructions
Patients with diseases accompanied by hyperkalemia require special attention: regular monitoring of the ionogram is required.
Influence on the ability to drive and perform work associated with an increased risk of injury: does not affect the ability to drive and engage in activities that require increased concentration and psychomotor speed.
Storage conditions
At a temperature of 15-30 ° C. Keep out of the reach of children.
Shelf life
5 years
